Anixa Biosciences, Inc. announced the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer. Dr. Garzone will oversee Anixa's vaccine and therapeutic development programs and will report to the CEO. Dr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech.